Neuronetics, Inc. announced that a new health economic study evaluating the cost effectiveness of its NeuroStar TMS Therapy system in the treatment of depression was presented at the U.S. Psychiatric and Mental Health Congress in San Diego last week.
Popularity: 1% [?]
Related posts:
- Landmark Results From Depression Efficacy Study To Be Presented By CNS Response At U.S. Psychiatric And Mental Health Congress
- 6-Week Study In Adults With Major Depressive Disorder Evaluates Effectiveness Of Adjunctive Aripiprazole Therapy With Antidepressants
- Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms In Adolescents
- FDA Clears NeuroStar(R) TMS Therapy For The Treatment Of Depression
- FDA Clears Neurostar® TMS Therapy For The Treatment Of Depression
Comments
No Responses to “New Study Demonstrates Cost Effectiveness Of NeuroStar TMS Therapy(R) In The Treatment Of Depression”